Report shows high confidence in their launch of epilesy drug. Very positive. This stock trades not on current anything, but on it's rosy future. It's in the 'price discovery' mode, oscillating around what is current fair value of around $13-14 as judged by market. Good trade to buy now that the uncertainty over what's in the ER is over.